alta-1l: brigatinib is superior to crizotinib in alk nsclc
Published 5 years ago • 216 plays • Length 2:18Download video MP4
Download video MP3
Similar videos
-
2:05
alta-1l: brigatinib vs crizotinib in nsclc
-
2:09
alta-1l: brigatinib vs crizotinib in alk ansclc
-
1:21
alta-1l: brigatinib vs crizotinib
-
4:00
alta-1l: final overall survival results of brigatinib vs crizotinib for alk lung cancer
-
6:58
alta-1l: brigatinib versus crizotinib for alk nsclc
-
3:04
management of frontline alk nsclc: brigatinib vs. alectinib
-
5:51
alta-1l: brigatinib vs crizotinib for alk advanced non small cell lung cancer patients
-
4:38
alta ii: brigatinib in crizotinib-resistant alk nsclc
-
2:39
why brigatinib was approved to treat alk non-small cell lung cancer?
-
2:13
alk nsclc: brigatinib indication and alta trial
-
3:41
alta-1l updates at esmo 2020: intracranial efficacy and hrqol
-
1:52
dr. drilon on the utility of brigatinib in alk nsclc
-
5:44
updates in alk lung cancer: glass, alex, alta-1l and crown
-
8:16
alta ii trial of brigatinib in alk-rearranged nsclc
-
5:28
crown study: lorlatinib vs crizotinib in 1l nsclc
-
4:15
nice approval: brigatinib in alk nsclc
-
1:38
dr. drilon on the safety profile of brigatinib in alk nsclc
-
1:22
dr. campelo on the rationale for the alta-1l trial
-
1:34
dr. camidge on the alta study of brigatinib in nsclc